Financial Performance - The company's revenue for Q1 2024 was CNY 122,227,974.51, representing a 2.35% increase compared to CNY 119,423,435.11 in the same period last year[5] - Net profit attributable to shareholders decreased by 11.86% to CNY 3,547,307.04 from CNY 4,024,418.08 year-on-year[5] - Total operating revenue for Q1 2024 was CNY 122,227,974.51, an increase of 2.26% compared to CNY 119,423,435.11 in Q1 2023[17] - Net profit for Q1 2024 was CNY 2,893,085.07, a decrease of 20.83% from CNY 3,651,134.29 in Q1 2023[18] - Total operating costs for Q1 2024 were CNY 122,389,251.15, up from CNY 120,171,920.93, reflecting a rise of 1.83%[17] Cash Flow - The net cash flow from operating activities improved by 57.80%, reaching CNY -24,222,072.61, compared to CNY -57,394,913.52 in the previous year[10] - Operating cash flow for Q1 2024 showed a net outflow of CNY -24,222,072.61, an improvement from CNY -57,394,913.52 in Q1 2023[19] - Cash inflow from operating activities totaled CNY 157,223,568.99, compared to CNY 120,839,809.00 in the previous year, marking an increase of 30.06%[19] - The net cash flow from financing activities surged by 561.08% to CNY 45,285,025.70, compared to CNY 6,850,178.56 in the previous year, reflecting reduced cash outflow for debt repayment[11] - The net cash flow from investing activities for Q1 2024 was -58,131,796.22, compared to -148,163,433.78 in the same period last year[20] - The cash outflow for financing activities totaled 41,714,974.30, compared to 123,527,591.55 in Q1 2023[20] - The cash inflow from borrowing was 87,000,000.00, reflecting a decrease from the previous year's 130,377,770.11[20] Assets and Liabilities - Total assets increased by 1.26% to CNY 2,478,579,378.33 from CNY 2,447,740,699.18 at the end of the previous year[5] - The total liabilities increased from ¥686,405,942.78 to ¥712,125,543.01, indicating a rise of approximately 3.7%[15] - Total liabilities as of March 31, 2024, were CNY 1,451,381,686.72, compared to CNY 1,423,965,109.22 at the end of Q1 2023, an increase of 1.94%[18] - The company’s total current assets amount to ¥772,701,690.45, down from ¥869,731,565.50 at the beginning of the period, representing a decrease of approximately 11.1%[15] - Cash and cash equivalents decreased from ¥181,973,811.45 to ¥116,793,029.53, a decline of about 35.8%[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,788[12] - The largest shareholder, Xi Zuobin, holds 31.72% of shares, totaling 36,567,000 shares[12] - The company has no preferred shareholders as of the reporting period[13] Other Financial Metrics - The company reported a significant increase of 2,911.68% in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to CNY 3,464,603.03 compared to CNY 115,039.00 last year[5] - The company’s weighted average return on equity decreased slightly to 0.37% from 0.43% year-on-year[5] - Research and development expenses for Q1 2024 were CNY 9,505,034.39, down from CNY 10,545,515.62, indicating a reduction of 9.85%[18] - The company reported a decrease in sales expenses to CNY 864,906.68 from CNY 868,263.18, a decline of 0.50%[17] - The company’s financial expenses for Q1 2024 were CNY 2,885,024.73, slightly up from CNY 2,868,072.48, indicating a marginal increase of 0.59%[18] Exchange Rate Impact - The company reported a 1346.65% increase in the impact of exchange rate changes on cash and cash equivalents, amounting to CNY 271,084.66[11] - The cash flow impact from exchange rate changes was 271,084.66, compared to 18,738.78 in the previous year[20] - The company reported a significant decrease in cash and cash equivalents year-over-year, indicating potential liquidity challenges[20] Audit Information - The company did not undergo an audit for the Q1 2024 report[21]
共同药业(300966) - 2024 Q1 - 季度财报